

## Interactions of Membrane-Active Peptides with Thick, Neutral, Nonzwitterionic Bilayers

Kandaswamy Vijayan,<sup>†</sup> Dennis E. Discher,<sup>\*,‡,§</sup> Jyotsana Lal,<sup>||</sup> Paul Janmey,<sup>\*,§,⊥</sup> and Mark Goulian<sup>\*,†,§</sup>

Departments of Physics, of Chemical and Biomolecular Engineering, and of Physiology and Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, and IPNS Division, Argonne National Laboratory, 9700 South Cass Avenue, Argonne, Illinois 60439

Received: January 5, 2005; In Final Form: May 27, 2005

Alamethicin is a well-studied channel-forming peptide that has a prototypical amphipathic helix structure. It permeabilizes both microbial and mammalian cell membranes, causing loss of membrane polarization and leakage of endogenous contents. Antimicrobial peptide–lipid systems have been studied quite extensively and have led to significant advancements in membrane biophysics. These studies have been performed on lipid bilayers that are generally charged or zwitterionic and restricted to a thickness range of 3–5 nm. Bilayers of amphiphilic diblock copolymers are a relatively new class of membranes that can have significantly different physicochemical properties compared with those of lipid membranes. In particular, they can be made uncharged, nonzwitterionic, and much thicker than their lipid counterparts. In an effort to extend studies of membrane–protein interactions to these synthetic membranes, we have characterized the interactions of alamethicin and several other membrane-active peptides with diblock copolymer bilayers. We find that although alamethicin is too small to span the bilayer, the peptide interacts with, and ruptures, thick polymer membranes.

## Introduction

It is now very clear that a self-assembled bilayer of amphiphiles can be much thicker than the 3–5 nm that is typical of lipid bilayers. Indeed, diblock copolymers of the appropriate amphiphilic proportions assemble in water into vesicles (polymersomes) and can be made with hydrophobic cores up to 20 nm thick.<sup>1</sup> Copolymer membranes can also be made uncharged, nonzwitterionic, mechanically stronger, and chemically more inert than lipid bilayers. For many biotechnology applications, polymersomes appear to offer a number of advantages.<sup>1</sup> Analogies with biological membranes have guided much of the work on polymersomes, and initial work with detergents<sup>2</sup> has demonstrated a scaled resistance to disruption. A theoretical analysis of the energetics of inclusions in polymeric membranes suggests that it should be possible to incorporate membrane proteins into polymersomes even when there is a substantial mismatch between the hydrophobic thicknesses of the protein and bilayer.<sup>3</sup> Indeed, at least two membrane proteins (porins) have been successfully incorporated into a copolymer membrane.<sup>4</sup> However, interactions of diblock copolymers with well-characterized model protein and peptide systems have not yet been explored. It is not known, in particular, to what extent general features of protein–lipid bilayer interactions carry over to thick, neutral, nonzwitterionic block copolymer membranes.

We describe in this paper studies of the action of the membrane-active peptide alamethicin on polymersomes. Alamethicin is a well-studied antimicrobial peptide of 21 amino

acids from the fungus *Trichoderma viride*. It adopts a helical structure in both monomeric and helix–bend–helix dimeric forms that self-assemble in membranes into voltage-dependent<sup>5</sup> ion-conducting helix bundles. Alamethicin is also an antimicrobial agent<sup>6</sup> that acts on both microbes and mammalian cells by permeabilizing the cell membrane, causing leakage of endogenous contents and membrane depolarization.<sup>7</sup> The interaction of alamethicin with lipid bilayers has served as an important system for the study of basic properties of membrane–protein interactions, ion channels, and antimicrobial peptides and has continued to be studied quite extensively.<sup>5,8–14</sup> Past work has led to an elegant model for the action of alamethicin and other antimicrobial peptides<sup>10,15,16</sup> in which bilayer thinning leads to the formation of peptide-stabilized pores.

The polymer vesicles used in our experiments are composed of two different amphiphilic diblock copolymers, OE7 and OB18, which form membranes with 8 and 15 nm thick cores, respectively (Figure 1).<sup>17,18</sup> When dry films of the copolymers are hydrated in water, polymersomes form spontaneously.<sup>19</sup> Both copolymer membranes are significantly thicker than the ~4 nm thickness of a typical phosphatidylcholine (PC) lipid bilayer.<sup>20</sup>

We analyzed alamethicin–polymersome interactions with a host of complementary techniques. Peptide binding was monitored by a spectral shift of the fluorophore LAURDAN and by circular dichroism (CD), vesicle permeabilization or lysis was monitored by calcein leakage, and changes to vesicle and bilayer morphology were monitored by optical microscopy, dynamic light scattering, and neutron scattering. Given the importance of electrostatic interactions (for both charged and zwitterionic lipids) in the alamethicin–lipid system and the ability of alamethicin to span the lipid bilayer hydrophobic core, it is not clear a priori whether alamethicin would interact with polymer vesicles, which are neutral, nonzwitterionic, and have substantially thicker bilayers (Figure 1). However, we found that alamethicin binds to both the thinner (OE7) and thicker (OB18)

\* To whom correspondence should be addressed.


<sup>†</sup> Department of Physics, University of Pennsylvania.

<sup>‡</sup> Department of Chemical and Biomolecular Engineering, University of Pennsylvania.

<sup>§</sup> Institute for Medicine and Engineering, University of Pennsylvania.

<sup>||</sup> Argonne National Laboratory.

<sup>⊥</sup> Department of Physiology, University of Pennsylvania.



**Figure 1.** Relative size of the peptide and membranes. Alamethicin forms an amphiphilic helix that is only a few angstroms shorter than the  $\sim 3$  nm typical hydrophobic core thickness of lipid membranes. The hydrophobic core thickness of the OE7 (PEO–PEE) diblock copolymer membrane is around 8 nm as determined by cryo-TEM, and the corresponding thickness for OB18 (PEO–PBD) is  $\sim 14$  nm (not shown).<sup>18</sup>

membranes and induces lysis of vesicles at high peptide concentrations. We also found evidence of bilayer thinning prior to lysis, which is reminiscent of the behavior observed for lipid bilayers. The disruptive effects of alamethicin on neutral polymer vesicles indicate unanticipated interactions that suggest, for lipid membranes, more generic amphipathic insertion mechanisms.

## Materials and Methods

**Chemicals.** The diblock copolymers OE7, (poly(ethylene oxide))<sub>40</sub>–(poly(ethylene))<sub>37</sub> (number-averaged molecular weight  $M_n = 3700$ ), and OB18, (poly(ethylene oxide))<sub>80</sub>–(polybutadiene)<sub>125</sub> ( $M_n = 10400$ ), were synthesized by Hillmyer and Bates.<sup>18,21</sup> LAURDAN was purchased from Molecular Probes (Eugene, OR), and a stock solution of 20 mg/mL was made in chloroform, from which aliquots of 0.2 mg/mL (in chloroform) were prepared for use in actual experiments. Egg PC, calcein, alamethicin, melittin, polymyxin, and mastoparan were from Sigma (St. Louis, MO). The alamethicin from Sigma (product no. A4665) consists of the neutral alamethicin F50 peptide with trace amounts of the negatively charged alamethicin F30.<sup>22</sup> Alamethicin and melittin were dissolved in 20% methanol to 1 mg/mL, except for the neutron scattering experiments where 10 mg/mL stock solutions of alamethicin were made in 100% methanol. Deuterated water (Sigma) was used to prepare phosphate-buffered saline (PBS) solutions for neutron scattering experiments. Polymyxin and mastoparan were dissolved in distilled deionized water to make 1 mg/mL stock solutions.

**Vesicle Preparation.** Vesicles for all of the experiments were made by film rehydration.<sup>19</sup> Briefly, 1 mL of a 1 mg/mL solution of polymer or lipid dissolved in chloroform was uniformly coated on the inside wall of a glass vial. For the LAURDAN spectral shift experiment, 0.1 mol % LAURDAN was mixed with lipid or polymer in chloroform. The chloroform was evaporated in a stream of nitrogen and the film allowed to dry in a vacuum for 6–8 h. For LAURDAN and light scattering experiments, vesicles were swelled by adding 1 mL of PBS to the film and placing the vials in a 60 °C oven for 8 h, which led to budding of vesicles off the glass wall. After five cycles of freezing–thawing in dry ice and water at 37 °C, the vesicles

were made monodisperse by passing the suspension repeatedly through a vesicle extruder with a pore size (diameter) of 100 or 200 nm (Avestin Inc., Ottawa, Ontario, Canada). The average size and polydispersity were measured by dynamic light scattering. For neutron scattering experiments, vesicles were swelled in deuterated PBS. For the calcein leakage assay,<sup>23</sup> 50 mM calcein was made in Tris buffer and the pH was adjusted to 7.4 with NaOH. Vesicles were swelled by adding this solution to polymer or lipid films and following the above protocols. Nonencapsulated calcein was removed by dialysis prior to vesicle extrusion. Since there was no significant change in volume after dialysis, we have assumed the final polymer concentration was equal to the starting concentration. For microscopy, the polymer or lipid film was rehydrated in a  $\sim 150$  mOsm sucrose/H<sub>2</sub>O solution, frozen–thawed five times in dry ice and water at 37 °C, and viewed under phase contrast after dilution into PBS. In all cases for solutions of vesicles, molar concentration refers to the molar concentration of polymer molecules.

**Fluorescence Spectroscopy of LAURDAN.** LAURDAN-incorporated OE7 vesicles were added to 1.5 mL of PBS in a cuvette equipped with a small magnetic stir bar. The final concentration of polymersomes was either 2.5 or 5  $\mu$ M, and peptide was added in steps to obtain various concentration ratios of polymer or lipid to peptide. LAURDAN fluorescence was monitored with a Photon Technology International (Lawrenceville, NJ) spectrofluorometer.

**Calcein Leakage Assay.** Calcein-loaded vesicles were suspended in 1.5 mL of buffer (10 mM Tris/HCl, 3 mM EDTA, NaCl, pH 7.4). The amount of NaCl was chosen to match the osmolality of the calcein solution used to prepare the vesicles and was in the range of 150–200 mM. The final polymer concentration was between 5 and 10  $\mu$ M. Peptides were added in fixed concentration steps. The sample was stirred with a magnetic stir bar for a short time immediately after addition of peptides to ensure uniform mixing. Permeabilization or rupture was monitored through the increase in calcein fluorescence. Triton X100 detergent (0.6–1%) was used to cause complete lysis of vesicles. Normalized fluorescence ( $F_N$ ) was defined by  $F_N = [(F - F_B) \times 100] / (F_D - F_B)$ , where  $F_B$  is the baseline fluorescence before addition of peptide and  $F_D$  is the fluorescence obtained after detergent lysis.

**Circular Dichroism.** For CD measurements, a suspension of 200 nm diameter OE7 vesicles (42  $\mu$ M OE7) was added to a 300  $\mu$ L quartz cuvette with 1 mm optical path length. Alamethicin was added to the cuvette in steps, and the ellipticity (for wavelengths between 200 and 260 nm, at 1 nm intervals) was measured on an AVIV 62DS spectropolarimeter. Background signal from the buffer was subtracted before processing of the data. The helical content of the peptide was monitored from the ellipticity of the solution at 222 nm. For each peptide concentration, the ellipticity of the sample containing vesicles and alamethicin ( $\theta_{222}$ ) was subtracted from the corresponding ellipticity for a suspension of pure alamethicin ( $\theta_{222, \text{Alam}}$ ).

**Dynamic Light Scattering.** Dynamic light scattering (DLS) was performed on a Protein Solutions, DynaPro MS/X instrument (Proterion Corp., Piscataway, NJ). Samples were placed in a quartz cuvette with an effective sample volume of 50  $\mu$ L. The concentration of vesicles used was typically 3–5  $\mu$ M in PBS. Peptides were added to the cuvette and rapidly mixed by drawing the solution in and out of the pipet several times. The samples were placed in the DLS instrument immediately after mixing. The DynaPro Dynamics software included with the instrument was used to extract the distribution of vesicle sizes

(hydrodynamic radii) from the light scattering signal. This software uses a proprietary algorithm to determine the distribution of particle sizes that is similar to the algorithm used in the Dynals software.<sup>24</sup>

**Microscopy and Micromanipulation.** Video microscopy was performed on a Nikon TE-300 inverted microscope equipped with phase contrast. Image collection through a 40 $\times$  or 60 $\times$  objective lens was accomplished with a CCD video camera mounted on the front port of the microscope. A custom manometer with pressure transducers (Validyne, Northridge, CA) was used for controlling and maintaining pressure to the micropipet as in refs 19 and 25. Micropipets, with tip diameters of 5 or 10  $\mu\text{m}$ , were prepared as in refs 19 and 25. Fractional membrane thinning was determined from the increase in membrane projection inside the micropipet by % thinning =  $r(\Delta l)/(2R^2 + r l_i)$ , where  $\Delta l$  is the change in membrane projection inside the micropipet,  $l_i$  is the initial aspirated length,  $r$  is the pipet radius, and  $R$  is the vesicle radius. This formula is based on the assumption that the hydrophobic core of the membrane is incompressible and that the volume change of the vesicle is negligible.<sup>26</sup>

**Neutron Scattering.** Neutron scattering measurements from polymersomes were performed at the time-of-flight small angle diffractometer (TOF-SAD) at IPNS, Argonne National Laboratory, Argonne, IL. The time-resolved detector used in the TOF-SANS (SANS = small-angle neutron scattering) instrument enables simultaneous measurement of scattering in a large  $Q$  (wavenumber) range from a single pulse of polychromatic neutrons, thus reducing the time the sample has to be kept in the neutron beam. Scattering density contrast between the polymer bilayer and the surrounding medium was obtained by preparing the vesicles in deuterated PBS. Experiments were performed at 25  $^\circ\text{C}$  in circular quartz cells of 2 mm path length. The concentration of vesicles was 2 mg/mL, and the samples were placed in the neutron beam for at least 6 h to collect reliable scattering statistics.

## Results

**Blue-Shifted LAURDAN Emission.** LAURDAN is an amphiphilic fluorophore that has been used to assess interfacial perturbations and phase changes in both liposomes<sup>27</sup> and polymersomes.<sup>19</sup> When LAURDAN incorporates into membranes, the molecule's lauric acid chain pulls the chromophore into the hydrophobic core of the bilayer just beneath the lipid/water (polymer/water) interface. Fluorescence excitation leads to a localized charge separation that couples dissipatively to surrounding dipoles. As a result, the LAURDAN emission spectrum is sensitive to the strength of this coupling. For example, changes that result in decreased water accessibility, e.g., as a result of adding organic solvents, will result in a blue shift of the emission spectrum.<sup>19</sup>

Addition of alamethicin to LAURDAN-labeled PC vesicles caused a blue shift in the LAURDAN emission spectrum (Figure 2A). Likewise, when alamethicin was added to LAURDAN-containing polymer vesicles, a blue shift was also seen (Figure 2A,B). This clearly indicates that alamethicin is able to penetrate the polymersome's hydrophilic brush and partition into the bilayer interface. Since the alamethicin was dissolved in methanol, control experiments were performed in which identical amounts of methanol (up to 0.01 vol %) were added without alamethicin. No spectral shift was observed in this case. For PC vesicles, the blue shift was detectable above a threshold molar ratio of alamethicin to PC of approximately 1:20 (Figure 2A). The effect saturated at higher concentrations. In the absence

of peptide, the LAURDAN emission spectrum from OE7 vesicles was red-shifted relative to the spectrum from PC vesicles (maxima at 480 and 470 nm for OE7 and PC, respectively). This suggests that LAURDAN is exposed to a more polar environment in the OE7 membrane. No blue shift was seen below a 1:5 molar ratio of alamethicin to OE7.


All of the LAURDAN–OE7 emission spectra intersect at the same point as the alamethicin concentration is varied (Figure 2B). This behavior was not observed in PC–LAURDAN spectra nor in OB18–LAURDAN spectra. A simple explanation for this behavior is that at intermediate levels of alamethicin the samples consist of two populations: one has an unshifted LAURDAN spectrum, and the other has a blue-shifted spectrum. As alamethicin is varied the relative abundance of the two populations varies from 100% unshifted population (e.g., no alamethicin added) to 100% blue-shifted population (e.g., 2.5  $\mu\text{M}$  alamethicin). To test this, we fitted each spectrum to a linear combination of the unshifted (no alamethicin) and blue-shifted (5  $\mu\text{M}$  alamethicin) spectra (Figure 2C). All of the spectra gave good fits to within experimental error (representative fits are shown in Figure 2C), indicating that there are indeed two distinct populations. This could reflect two different populations of LAURDAN within each vesicle, e.g., due to two different peptide–copolymer phases in the membrane, or alternatively it may reflect two different LAURDAN-containing polymer structures, e.g., coexisting polymersomes and micelles.

LAURDAN incorporates into PC and OE7 bilayers at a fairly low concentration of 0.05 mol %. At similar LAURDAN concentrations in OB18 membranes the fluorescence was very low and noisy. Spectral shift experiments in OB18 were therefore performed with 1 mol % LAURDAN. LAURDAN has an emission peak at 470 nm in OB18, which is closer to the emission peak of LAURDAN in PC than that of LAURDAN in OE7. This may indicate that for OB18 the LAURDAN molecules are trapped deep within the polymer brush and are well-shielded from water. Alamethicin causes a strong blue shift in OB18 membranes that saturates at an approximately 1:1 ratio of peptide to polymer (Figure 2A).

In addition to alamethicin, three other antimicrobials were added to LAURDAN-containing OE7 vesicles (Table 1). Polymyxin did not alter the spectral properties of LAURDAN in any way. Mastoparan and mellitin, two peptides that are known to form toroidal pores in lipid membranes, showed relatively weak blue shifts (Figure 2D).

**Calcein Leakage.** Calcein leakage is a well-established assay for studying vesicle permeabilization.<sup>23</sup> Vesicles loaded with a high concentration (50 mM) of the fluorescent compound calcein show substantial self-quenching. Permeabilization or rupture leads to a drop in calcein concentration and an increase in fluorescence. For our experiments, fluorescence emission was normalized by the fluorescence after detergent lysis. Addition of a high concentration of alamethicin to calcein-loaded PC vesicles showed rapid and complete leakage (Figure 3A), which is consistent with previous studies.<sup>28</sup> Surprisingly, we found that alamethicin was also able to permeabilize OE7 vesicles (Figure 3B). Addition of alamethicin to a molar ratio of 1:2 (alamethicin:OE7) caused a partial increase in fluorescence (Figure 3B). The kinetics varied from sample to sample of OE7 vesicles (data not shown). However, over a period of 1/2 h, the extent of leakage was comparable (within 20%) across samples. The order of addition did not matter; i.e., addition of OE7 vesicles to an alamethicin solution gave similar results, ruling out the possibility that the incomplete lysis is due to a transient high concentration of peptide upon addition of peptide to the





**Figure 2.** LAURDAN spectral shift. (A) Addition of alamethicin to PC, OE7, and OB18 vesicles causes LAURDAN emission maxima to blue shift. The data for PC are shown in the inset. A threshold concentration below which alamethicin did not result in a detectable blue shift was observed for PC and OE7. (B) Emission spectra of LAURDAN incorporated into OE7 vesicles with different concentrations of alamethicin. Note that the curves intersect at a common point. The arrows denote directions of increasing molar ratio of alamethicin to OE7. (C) Two-population fits for blue-shifted LAURDAN spectra. The fits were determined with the formula  $F_i = \alpha F_0 + (1 - \alpha)F_\infty$ , where  $\alpha$  is the fitting parameter,  $F_0$  is the spectrum in the absence of alamethicin, and  $F_\infty$  is the spectrum with a saturating concentration of alamethicin, which we took to be 2:1 alamethicin to OE7. The values for  $\alpha$  determined from the fits are shown in the table on the right. Representative fits are shown in the graph on the left. (D) LAURDAN blue shift for three other membrane-active peptides added to OE7 vesicles. Melittin and mastoparan are two antimicrobial peptides that are also known to permeabilize lipid vesicles. They both show weak blue shifts, indicating at least some interaction with the OE7 bilayer. Polymyxin, an antibacterial agent that binds to lipopolysaccharides found in Gram-negative bacterial cell walls, does not affect the spectral properties of LAURDAN in the bilayer.


**TABLE 1**

peptide	PC			OE7			OB18		
	LAURDAN emission peak	calcein leakage	DLS	LAURDAN emission peak	calcein leakage	DLS	LAURDAN emission peak	calcein leakage	DLS
alamethicin	blue shifts	leaks	ruptures	blue shifts	leaks	ruptures	blue shifts	no leak	no change
melittin	blue shifts	leaks	ruptures	blue shifts	no leak	no change	no change	no leak	no change
mastoparan	blue shifts	leaks	no change	blue shifts	no leak	no change	no change		no change
polymyxin		no leak	no change	no change	no leak	no change	no change		no change

polymersome solution. Alamethicin did not cause any leakage from OB18 vesicles, even at concentrations of 1:1 (Figure 3C).

Leakage from OE7 vesicles was not observed below a threshold molar ratio of  $\sim 1:4$  (alamethicin:OE7) (Figure 4). In addition, unlike the case for PC vesicles, complete leakage from

OE7 vesicles occurred only at extremely high alamethicin concentrations (5:1 or more). When alamethicin was added at intermediate concentrations in steps of  $2 \mu\text{M}$  to a solution of calcein-loaded OE7 vesicles ( $15 \mu\text{M}$  OE7), the extent of leakage varied with each addition of peptide. Sometimes adding ala-




**Figure 3.** Representative graphs of alamethicin-induced calcein leakage. Fluorescence was normalized by the fluorescence level after detergent lysis (0.6% Triton X100). The arrows indicate the instant at which the peptide or detergent was added. The concentration of peptide is represented as a molar ratio (alamethicin to polymer or lipid). (A) Alamethicin induces 100% leakage from 200 nm PC vesicles. (B) Alamethicin induces partial calcein leakage from 200 nm OE7 vesicles. (C) Alamethicin does not induce calcein leakage from 200 nm OB18 vesicles.


methicin caused no further increase in fluorescence while the fluorescence level would increase with the next dose of peptide. These observations are consistent with subpopulations of vesicles with varying degrees of susceptibility to alamethicin.

We also looked at the effects of mellitin, mastoparan, and polymyxin on calcein-loaded OE7 polymersomes. None of these peptides showed any evidence of calcein leakage for molar ratios up to 1:1 (data not shown).

**Circular Dichroism.** The calcein leakage results indicate that alamethicin permeabilizes OE7 vesicles. However, this permeabilization occurs only at relatively high peptide concentrations. This may indicate that alamethicin has a low affinity for the polymer bilayer. Alternatively, it may indicate that a very large amount of bound alamethicin is required for polymersome permeabilization. The former view is supported by the LAURDAN experiments, which showed a significant blue shift for OE7 polymersomes only at a high alamethicin concentration. Partitioning of alamethicin into lipid bilayers is




**Figure 4.** Calcein leakage from OE7 vesicles as a function of alamethicin concentration. Below a threshold molar ratio of about 0.25, alamethicin does not cause any leakage from OE7. Complete leakage is not observed except at very high concentrations. The amount of leakage varies between different samples of OE7 polymersomes, with a maximum variation of about 20%.



**Figure 5.** Circular dichroism measurements of alamethicin in the presence of OE7 polymersomes. The ellipticity at 222 nm ( $\theta_{222}$ ) was determined for various molar ratios of alamethicin to OE7 and subtracted from the corresponding ellipticity for a solution of alamethicin alone ( $\theta_{222, \text{Alam}}$ ). For all measurements, the OE7 concentration was 42  $\mu\text{M}$ .


associated with an increase in the helical structure of the peptide, which can be detected by a corresponding increase in ellipticity (see, e.g., ref 29). We therefore carried out circular dichroism measurements on suspensions of OE7 polymersomes with various levels of alamethicin (Figure 5). There was a sharp increase in ellipticity at a molar concentration ratio of  $\sim 1:3$  (alamethicin:OE7). If we assume that, as in the case of lipid bilayers, binding of alamethicin to OE7 bilayers is associated with an increase in helical content of the peptide, then this result suggests that the peptide has very weak affinity for the bilayer at low peptide concentrations. Interestingly, the sharp rise in ellipticity at a threshold concentration suggests binding to the copolymer membrane is a strongly cooperative process. There is also a second increase in ellipticity at very high peptide concentration ( $\sim 1.5:1$  alamethicin:OE7). This could indicate a change in phase of the copolymer–alamethicin mixture to a nonbilayer form that is able to bind more peptide.

**Microscopy and Micromanipulation.** To directly visualize the effects of alamethicin on vesicles, large ( $\sim 15 \mu\text{m}$ ), phase-dark liposomes and polymersomes were prepared in which the lumen was loaded with a sucrose solution that matched the osmolarity of the phosphate buffer on the outside ( $\sim 290 \text{ mOsm}$ ). The refractive index difference between the vesicle interior and exterior provided contrast for phase contrast microscopy. When alamethicin at a 1:2 concentration ratio was added to PC and OE7 vesicles while they were being imaged under the microscope, the vesicles were observed to lyse. To study individual vesicles in more detail, micromanipulation techniques were



**Figure 6.** Micropipet delivery of alamethicin. (A) Alamethicin was allowed to diffuse freely from a micropipet placed near an OE7 vesicle. Phase contrast was achieved by loading the lumen with a sucrose solution that was equiosmotic to the surrounding PBS buffer. The pipet contained alamethicin at 0.05 mg/mL. No phase loss was observed before disintegration of the vesicle. Instead, a dramatic collapse occurred, triggered by the loss of membrane integrity at one spot on the vesicle. (B) An OE7 vesicle was held in a micropipet, and alamethicin was allowed to diffuse from a second pipet. The amount of membrane aspirated into the pipet increased with time until vesicle rupture, while the radius of the vesicle remained unchanged. (The scale is the same as in (A).)

used.<sup>30,31</sup> Alamethicin at 0.05 mg/mL was loaded into a micropipet and moved into a chamber containing lipid or polymer vesicles. The pipet was then positioned close to a vesicle, and peptide was allowed to diffuse out. For OE7 vesicles, membrane disintegration was observed at one spot on the membrane, followed by an abrupt and dramatic collapse of the whole vesicle (Figure 6A). Vesicle shape fluctuations occurred just before collapse. To study OE7 lysis more closely, an apparatus with two micropipets was used. An OE7 vesicle was held aspirated by a micropipet while peptide was allowed to diffuse from a second pipet that was positioned next to the vesicle (Figure 6B). We found that, as alamethicin was released, the amount of OE7 membrane that was pulled into the pipet increased with time until the vesicle ultimately ruptured. At the same time, however, the radius of the vesicle did not change (Figure 6B). This apparent increase in membrane area may be due to incorporation of alamethicin into the bilayer, with concomitant membrane thinning. (Similar observations for PC vesicles in the presence of other peptides have been made.<sup>32</sup>) Bilayer thinning was calculated from the increase in membrane projection inside the micropipet (see the Materials and Methods). We found that the percentage thinning at the time of rupture was a decreasing function of the size of the vesicles (Figure 7). Since the alamethicin was allowed to diffuse freely from the second micropipet in all experiments, this observation could be due to the high local ratio of alamethicin to polymer in




**Figure 7.** Membrane thinning due to micropipet delivery of alamethicin. The increase in membrane surface area due to the increase in membrane inside the micropipet can be used to estimate the extent of bilayer thinning if we assume the hydrophobic core of the bilayer is incompressible. The thinning just prior to rupture is plotted as the percentage of initial membrane thickness vs vesicle diameter.

smaller vesicles. The range of thinning calculated is from 2% to 14% of the original thickness. These polymersomes have been reported to rupture at pipet-imposed area strains of ~20%.<sup>19</sup>


For PC vesicles exposed to 0.05 mg/mL alamethicin, loss of phase contrast was gradual and preceded loss of membrane integrity (Figure 8A). Smaller vesicles trapped inside larger PC vesicles were expelled, indicating the presence of large pores. As noted above, phase loss and lysis were simultaneous for OE7 vesicles. When alamethicin at these same concentrations was delivered locally to OB18 vesicles by a micropipet, no change in morphology or phase contrast was observed. However, when OB18 vesicles were transported into a bath of 0.8 mg/mL alamethicin, phase loss and membrane curling were observed (Figure 8B). Alamethicin appears to rupture OB18 vesicles only at extremely high concentrations of peptide.

**Dynamic Light Scattering.** To examine the effect of alamethicin on the morphology of the smaller vesicles used in the LAURDAN and calcein experiments, we used dynamic light scattering. Data were analyzed assuming scattering from spherical objects, which were characterized by their hydrodynamic radii. It is possible that, after addition of peptide, part of the light scattering was in fact from nonspherical bilayer or micellar structures. Nevertheless, representation of the scattering data as a distribution of hydrodynamic radii provides a convenient measure of changes in vesicle morphology. Representative size distribution histograms for 100 nm vesicles in the presence of alamethicin are shown in Figure 9. For PC vesicles, a change in the distribution was only observed for an alamethicin to PC molar ratio above 1:20 (data not shown). Populations of larger and smaller sizes were evident, suggesting rupture and reaggregation. For OE7, there appeared to be a threshold molar ratio of roughly 1:4 (alamethicin to polymer) below which no significant change in the size distribution was observed. Adding alamethicin to OB18 vesicles did not cause any significant change in the vesicle size distribution even at 1:1 molar ratios. Mellitin, mastoparan, and polymyxin did not show any effect on light scattering from OE7 vesicles (data not shown).

**Neutron Scattering.** To examine the effect of alamethicin at small length scales (on the order of the bilayer thickness), neutron scattering was used (see, e.g., ref 33). Addition of alamethicin caused a significant shift in the scattering profile for molar ratios above 1:4 (Figure 10A). With increasing alamethicin, the location of the scattering intensity minimum in the  $I$  vs  $Q$  plot ( $Q_{\min}$ ) shifted toward larger wavenumbers. The corresponding length scale  $2\pi/Q_{\min}$  shifted by ~30 Å over




**Figure 8.** (A) Alamethicin was allowed to diffuse locally near a PC vesicle. Loss of phase contrast was observed before vesicle disintegration. Smaller vesicles trapped inside the larger vesicle were pushed out prior to complete lysis of the large vesicle. (B) Phase loss followed by lysis of an OB18 vesicle placed in a bath of 0.8 mg/mL alamethicin. OB18 is inert to alamethicin except at very high concentrations of peptide.



**Figure 9.** Dynamic light scattering from 200 nm vesicles. The size distribution is plotted as mass fraction (assuming scattering from spherical particles) vs radius. (A) The size distribution shifts to higher values after addition of alamethicin to PC vesicles. This indicates possible rupture and reaggregation. (B) The size distribution broadens on addition of alamethicin to OE7 vesicles. (C) There is very little change in the size distribution after addition of alamethicin to OB18 vesicles.

the range of alamethicin concentrations studied (Figure 10B). If we interpret this length scale as corresponding to an effective



**Figure 10.** (A) Scattering intensity vs wavenumber ( $Q$ ) from neutron scattering experiments. The first minimum shifts toward larger  $Q$  (smaller length scale) with increasing alamethicin. (B) Length scale associated with the first minimum in the scattering intensity ( $2\pi/Q_{\min}$ ) as a function of the molar ratio of peptide to polymer.

bilayer thickness, then this would give a thickness of OE7 vesicles in the absence of alamethicin of 11.6 nm. Since this includes the hydrated corona, it is not surprising that it is thicker than the 8 nm core thickness. At molar ratios of 1:3 and 1:2 the effective bilayer thickness is 8.9 and 7.8 nm, respectively. Note however that, at least for the samples containing alamethicin, other copolymer morphologies such as micelles may be present. In this case the length scale  $2\pi/Q_{\min}$  may not have a simple interpretation in terms of a bilayer thickness.

## Discussion

The results here are the first to demonstrate interactions between a membrane-active peptide and thick, neutral, non-



zwitterionic copolymer bilayers. We find that alamethicin, a well-characterized pore-forming antimicrobial peptide, partitions into amphiphilic copolymer membranes and causes vesicle rupture. Using a variety of different experimental techniques—LAURDAN blue shift, calcein leakage, circular dichroism, dynamic light scattering, and neutron scattering—we consistently found a threshold concentration of  $\sim 1:4$ – $1:3$  molar ratio of alamethicin to OE7 copolymer below which this peptide does not affect these vesicles. The circular dichroism and LAURDAN data suggest that below this threshold the peptide does not partition into the copolymer bilayer. Partial leakage from calcein-encapsulated vesicles indicates permeabilization and/or rupture, while the change in vesicle size distribution observed by DLS strongly supports the rupture hypothesis. The LAURDAN, calcein, and DLS results for OE7 as well as PC and OB18 vesicles are summarized in Table 1. Large OE7 vesicles visualized under the microscope in phase contrast were also seen to rupture upon addition of alamethicin. Loss of phase contrast prior to rupture, which would indicate permeabilization, was never observed.

A reasonable hypothesis that accounts for many of the results is that, above a critical concentration, alamethicin irreversibly binds to and ruptures a subpopulation of OE7 vesicles, and the number of ruptured vesicles increases with increasing concentration of alamethicin. LAURDAN blue shift experiments further support this mechanism. A continuous blue shift in the LAURDAN–OE7 fluorescence emission spectrum was observed as the alamethicin concentration was increased above a  $1:4$  molar ratio. This blue shift can be decomposed into a linear combination of two spectra, one being the initial spectrum in the absence of any alamethicin, and the other the saturated spectrum at very high concentrations of alamethicin ( $5:1$ ). This observation suggests there are two populations of LAURDAN at intermediate concentrations of alamethicin: ruptured and unruptured vesicles perhaps.

Further insights into the mechanism of interaction and rupture at large and small length scales are found in the micropipet aspiration and neutron scattering experiments, respectively. In the micropipet experiments, the radius of the aspirated vesicle remained constant while the membrane projection inside the micropipet increased until the vesicle finally ruptured. We interpret this as being due to an increase in the vesicle surface area as a result of alamethicin partitioning into the hydrophobic–hydrophilic interface of the copolymer membrane. Since the hydrophobic core is incompressible, the area increase is accompanied by a thinning of the bilayer. Neutron scattering from 200 nm OE7 vesicles gave results that were consistent with an increase in membrane thinning with increasing alamethicin. However, in light of the above results, the neutron scattering data at the higher alamethicin concentrations most likely represent scattering from a mixture of intact and ruptured vesicles. Further information regarding the structure of the ruptured vesicles will be required to provide a more realistic analysis of the structure factor.

The above picture of alamethicin interaction with OE7 polymersomes is reminiscent of a model for the interaction of alamethicin and other antimicrobial peptides with lipid bilayers.<sup>15</sup> In this model, alamethicin adsorbs to the membrane surface and intercalates between the lipid headgroups. This results in an effective increase in membrane tension and bilayer thinning. As the concentration of alamethicin is increased, a threshold is reached beyond which it is energetically favorable for peptide to form membrane-spanning pores in a barrel stave fashion. This leads to bilayer permeabilization and, at high

alamethicin concentrations, vesicle lysis. In contrast with the case of lipid bilayers, we did not find any evidence that alamethicin forms stable pores in polymersomes. Within the context of the above model, this may be because alamethicin cannot span the 8 nm thick hydrophobic core of the OE7 bilayer. In addition, our CD results indicate that alamethicin does not gradually partition into the polymer bilayer but instead shows a strongly cooperative transition at a threshold concentration.

We also found that alamethicin interacts with OB18 vesicles, which have a core that is roughly twice that of OE7. A very strong LAURDAN blue shift was observed when alamethicin was added to LAURDAN-containing OB18 vesicles although, since we had to use a much higher concentration of LAURDAN (20-fold higher), it is difficult to compare these results with the PC and OE7 data. At molar concentrations of alamethicin to OB18 as high as  $1:1$  there was no evidence of lysis in calcein leakage experiments and no evidence of a change in vesicle morphology in DLS experiments. In microscopy experiments, phase loss and lysis of OB18 vesicles were observed only at extremely high concentrations of alamethicin. It thus appears that OB18 is largely inert to alamethicin, presumably as a result of the larger thickness of the OB18 bilayer.

Three other antimicrobial peptides, mellitin, polymyxin, and mastoparan, were tested for interaction with OE7 membranes. Melittin,<sup>34</sup> from bee venom, forms pores in lipid vesicles. Polymyxin,<sup>35</sup> a powerful antibacterial agent, kills bacteria by preferentially binding to lipopolysaccharides found in the cell walls of Gram-negative bacteria. Mastoparan,<sup>36</sup> from wasp venom, is a human nerve cell degranulizer and is also known to form pores and cause lipid flip-flop in liposomes. Mastoparan and melittin were found to interact with OE7 vesicles in LAURDAN blue shift experiments, but they did not lead to vesicle permeabilization or rupture. Polymyxin did not appear to have any effect on polymersomes. These results are summarized in Table 1. At present we do not have an explanation for the differences between these peptides and alamethicin in their reactivity toward OE7 bilayers. However, the fact that the alamethicin that we have used is predominantly neutral, with a minority component that is negatively charged, whereas the above peptides are positively charged, may be important.

The results described here are an important step toward developing peptides and proteins that can stably function in polymer bilayers. The fact that alamethicin is able to penetrate the neutral hydrophilic polymer brush and partition into the thick hydrophobic cores of polymersomes suggests that synthetic peptides could be designed that further mimic the behavior of alamethicin in lipid bilayers. In particular, derivatives of alamethicin that form longer amphipathic helices might form stable barrel stave pores that span the polymer bilayer. On the other hand, our observation that some peptide–polymersome systems are stable and do not lead to vesicle lysis suggests that, in contrast with lipid vesicles, polymersomes could be used to target, encapsulate, and/or deliver high concentrations of antimicrobial peptides to specific microbial cell surfaces or specific tissues. Finally, given the powerful computational tools that are available for the analysis of copolymer assemblies,<sup>3,37,38</sup> the alamethicin–polymersome system provides a new tool for testing models of membrane–protein interactions.

**Acknowledgment.** Funding was provided by The Nano-technology Institute of Pennsylvania (M.G., D.D.), NSF-MRSEC (D.D.), NIH Grant R01 HL67286 (P.J.), and NIH Grant R21 (D.D.). We thank Harry Bermudez for assistance with the



micropipet aspiration experiments and Bhodana Discher for assistance with circular dichroism measurements.

## References and Notes

- (1) Discher, B. M.; Won, Y. Y.; Ege, D. S.; Lee, J. C.; Bates, F. S.; Discher, D. E.; Hammer, D. A. *Science* **1999**, *284*, 1143.
- (2) Pata, V.; Ahmed, F.; Discher, D. E.; Dan, N. *Langmuir* **2004**, *10*, 3888.
- (3) Pata, V.; Dan, N. *Biophys. J.* **2003**, *85*, 2111.
- (4) Meier, W.; Nardin, C.; Winterhalter, M. *Angew. Chem., Int. Ed.* **2000**, *39*, 4599.
- (5) Duclohier, H.; Wroblewski, H. *J. Membr. Biol.* **2001**, *184*, 1.
- (6) Kamysz, W.; Okroj, M.; Lukasiak, J. *Acta Biochim. Pol.* **2003**, *50*, 461.
- (7) Ritov, V. B.; Tverdislova, I. L.; Avakyan, T.; Menshikova, E. V.; Leikin Yu, N.; Bratkovskaya, L. B.; Shimon, R. G. *Gen. Physiol. Biophys.* **1992**, *11*, 49.
- (8) Spaar, A.; Munster, C.; Salditt, T. *Biophys. J.* **2004**, *87*, 396.
- (9) Kessel, A.; Tieleman, D. P.; Ben-Tal, N. *Eur. Biophys. J.* **2004**, *33*, 16.
- (10) Chen, F. Y.; Lee, M. T.; Huang, H. W. *Biophys. J.* **2003**, *84*, 3751.
- (11) Tieleman, D. P.; Hess, B.; Sansom, M. S. *Biophys. J.* **2002**, *83*, 2393.
- (12) Bak, M.; Bywater, R. P.; Hohwy, M.; Thomsen, J. K.; Adelhorst, K.; Jakobsen, H. J.; Sorensen, O. W.; Nielsen, N. C. *Biophys. J.* **2001**, *81*, 1684.
- (13) Huang, H. W. *Novartis Found. Symp.* **1999**, *225*, 188.
- (14) Dan, N.; Safran, S. A. *Biophys. J.* **1998**, *75*, 1410.
- (15) Huang, H. W.; Chen, F. Y.; Lee, M. T. *Phys. Rev. Lett.* **2004**, *92*, 198304.
- (16) Lee, M. T.; Chen, F. Y.; Huang, H. W. *Biochemistry* **2004**, *43*, 3590.
- (17) Discher, D. E.; Eisenberg, A. *Science* **2002**, *297*, 967.
- (18) Bermudez, H.; Brannan, A. K.; Hammer, D. A.; Bates, F. S.; Discher, D. E. *Macromolecules* **2002**, *35*, 8203.
- (19) Lee, J. C.; Bermudez, H.; Discher, B. M.; Sheehan, M. A.; Won, Y. Y.; Bates, F. S.; Discher, D. E. *Biotechnol. Bioeng.* **2001**, *73*, 135.
- (20) *Structure and Dynamics of Membranes—From Cells to Vesicles*, vol. 1 of the *Handbook of Biological Physics*; Lipowsky, R., Sackmann, E., Eds.; Elsevier Science: Amsterdam, 1995; kindly note pp 19 and 229 of this reference for thicknesses of phospholipid membranes.
- (21) Hillmyer, M. A.; Bates, F. S. *Macromolecules* **1996**, *29*, 6994.
- (22) Kirschbaum, J.; Krause, C.; Winzheimer, R. K.; Bruckner, H. *J. Pept. Sci.* **2003**, *9*, 799.
- (23) Kendall, D. A.; MacDonald, R. C. *J. Biol. Chem.* **1982**, *257*, 13892.
- (24) Golden, A. Dynals v1.0 white paper 2002. <http://www.alango.com>.
- (25) Aranda-Espinoza, H.; Bermudez, H.; Bates, F. S.; Discher, D. E. *Phys. Rev. Lett.* **2001**, *87*, 208301.
- (26) Kwok, R.; Evans, E. *Biophys. J.* **1981**, *35*, 637.
- (27) Bagatolli, L. A.; Gratton, E. *Biophys. J.* **2000**, *78*, 290.
- (28) Matsuzaki, K.; Shioyama, T.; Okamura, E.; Umemura, J.; Takenaka, T.; Takaishi, Y.; Fujita, T.; Miyajima, K. *Biochim. Biophys. Acta* **1991**, *1070*, 419.
- (29) Kikukawa, T.; Araiso, T. *Arch. Biochem. Biophys.* **2002**, *405*, 214.
- (30) Evans, E.; Heinrich, V.; Ludwig, F.; Rawicz, W. *Biophys. J.* **2003**, *85*, 2342.
- (31) Choi, M. J.; Kang, S. H.; Kim, S.; Chang, J. S.; Kim, S. S.; Cho, H.; Lee, K. H. *Peptides* **2004**, *25*, 675.
- (32) Longo, M. L.; Waring, A. J.; Hammer, D. A. *Biophys. J.* **1997**, *73*, 1430.
- (33) Balgavy, P.; Dubnickova, M.; Kucerka, N.; Kiselev, M. A.; Yaradaikin, S. P.; Uhrikova, D. *Biochim. Biophys. Acta* **2001**, *1512*, 40.
- (34) Yang, L.; Harroun, T. A.; Weiss, T. M.; Ding, L.; Huang, H. W. *Biophys. J.* **2001**, *81*, 1475.
- (35) Wiese, A.; Munstermann, M.; Gutschmann, T.; Lindner, B.; Kawahara, K.; Zahringer, U.; Seydel, U. *J. Membr. Biol.* **1998**, *162*, 127.
- (36) Arbuzova, A.; Schwarz, G. *Biochim. Biophys. Acta* **1999**, *1420*, 139.
- (37) Muller, M.; Katsov, K.; Schick, M. *Biophys. J.* **2003**, *85*, 1611.
- (38) Muller, M.; Katsov, K.; Schick, M. *J. Chem. Phys.* **2002**, *116*, 2342.